Related references
Note: Only part of the references are listed.Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
Susan L. Samson et al.
PITUITARY (2021)
Long-term safety and efficacy of long-acting pasireotide in acromegaly
Amit Akirov et al.
ENDOCRINE (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis
Mattia Barbot et al.
PITUITARY (2020)
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
Monica R. Gadelha et al.
ENDOCRINE CONNECTIONS (2020)
How to Position Pasireotide LAR Treatment in Acromegaly
Eva C. Coopmans et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study
Ammar Muhammad et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Diagnosis and Treatment of Pituitary Adenomas A Review
Mark E. Molitch
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry
Roberto Salvatori et al.
PITUITARY (2017)
Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
Maria Fleseriu et al.
ENDOCRINE (2017)
Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
Herbert A. Schmid et al.
ENDOCRINE (2016)
Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
Emmanuelle Kuhn et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
Michael Sheppard et al.
PITUITARY (2015)
Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study
Astrid Breitschaft et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Cardiometabolic Phenotyping of Patients With Familial Hypocalcuric Hypercalcemia
Peter Wolf et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients
Orsalia Alexopoulou et al.
PITUITARY (2014)
Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations
Annamaria Colao et al.
PITUITARY (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers
Robert R. Henry et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Somatostatin Secreted by Islet δ-Cells Fulfills Multiple Roles as a Paracrine Regulator of Islet Function
Astrid C. Hauge-Evans et al.
DIABETES (2009)
Oral Disposition Index Predicts the Development of Future Diabetes Above and Beyond Fasting and 2-h Glucose Levels
Kristina M. Utzschneider et al.
DIABETES CARE (2009)
Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Niels Moller et al.
ENDOCRINE REVIEWS (2009)
Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies
Gherardo Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Share Paper
